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INTRODUCTION
Prostaglandin-timolol fixed combinations (PTFCs) were 
introduced several years ago to improve adherence to 
chronic topical medical therapy in glaucoma (1). Published 
work has stressed that between 28% and 55% of patients 
do not adhere to their prescribed treatment regimen (2). 
Insufficient adherence may diminish efficacy, lead to glau-
coma progression, and contribute to the current incidence 
of blindness among glaucoma patients. A recent meta-
analysis of medical therapeutic trials has shown that non-
adherence to medical therapy is reduced by 24%-26% 
with fixed-dose combination regimens, compared with 
unfixed concomitant therapies (3). Theoretically, topical 
fixed combinations should provide similar advantages in 
glaucoma treatment as in other fields of medicine. Nev-
ertheless, as yet the precise impact on adherence of all 
glaucoma fixed combinations remains to be determined. 
Although the available information relevant to fixed com-
binations is increasing rapidly, comprehensive evidence is 
needed to demonstrate to what extent this class of medi-
cations improves adherence, decreases adverse events, 
and improves long-term clinical outcome.
The availability of the PTFCs has simplified adjunctive 
medication regimens. These combinations generally offer 
more intraocular pressure (IOP) lowering than each of their 
components alone, whereas their safety profile is almost 
as good as their individual constituents (1). Importantly, 
in real life practice these combinations may provide bet-
ter IOP control in some patients than unfixed concomitant 
therapy. Presumably this is due to the combined effects 
of enhanced convenience, elimination of the washout ef-
fect from the second drop, and improved adherence. Nev-
ertheless, although PTFCs generally demonstrate greater 
efficacy than each of their individual components, the en-
hanced reduction in IOP with these medications has been 
less than was originally anticipated. This may be due, at 
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least in part, to the potency of prostaglandin analogues, 
when used as monotherapy, and the use of timolol only 
once daily in PTFCs. It should also be borne in mind that to 
date there is limited published information evaluating the 
complete efficacy of PTFCs beyond 2-3 timepoints during 
the daytime. Interestingly, comparisons over 24 hours have 
generally demonstrated greater efficacy for these fixed 
combinations compared with their prostaglandin constitu-
ents (4-6). Other factors (time of administration, methodol-
ogy of studies, baseline IOP) may also play a part in these 
comparisons. To remove this ambiguity, in the future it will 
be important to assess the therapeutic equivalence of PT-
FCs versus unfixed therapy throughout the 24-hour period. 
Studies are also needed to evaluate the efficacy of this 
therapeutic category over the long term.
In the current ophthalmic literature it is generally difficult 
to assess and critically compare the efficacy reported 
for each fixed combination. There is no perfect unifor-
mity among registration trials and it is even more difficult 
to compare results from diverse phase IV trials. This is a 
common problem in medicine since the enormous growth 
of biomedical publications has yielded a massive literature 
that is beyond the ability of the average clinician to handle. 
Practicing physicians seeking answers to specific queries 
commonly find an excess of material of varying quality 
and conflicting findings that make clinical decision-making 
complex. The interpretation is limited by the presence of 
numerous small studies, which often do not reach either 
statistical significance or clinically meaningful outcomes.
Meta-analysis, a statistical method of combining the re-
sults of multiple studies, can harmonize this discordant 
literature. It provides the potential to address questions 
that individual studies lack the power to address. Most 
importantly, it offers a framework to investigate and ex-
plain between-study heterogeneity, potentially affording 
insights into the mechanisms of effects and a means to 
identify populations most likely to benefit from a specific 
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the differences between 2 study drugs are pooled, but the 
IOP decreases for each of the study drugs are not report-
ed. Thus, here one knows the differences between drugs, 
but no information is provided for the relative IOP-lowering 
effect of a PTFC. Figure 2 is useful in illustrating one of the 
key issues in this field of research: many studies have been 
conducted, but only a few address the issue of a head-to-
head comparison.
As always, with scientific evidence, the interpretation of this 
comprehensive meta-analysis is limited by certain factors. 
Although it was a network meta-analysis no indirect com-
parisons were used. Network meta-analysis (or multiple 
treatment meta-analysis) is an extension of the meta-analy-
sis methodology to more than 2 comparisons (20, 21). It can 
provide estimates of treatment efficacy of multiple treatment 
regimens, even when direct comparisons are unavailable by 
indirect comparisons (i.e., by contrasting the treatments of 
interest with a common reference and deducing their rela-
tive effects). Further, there needed to have been a better de-
scription of the included papers with respect to the study 
design. For instance, in some of the studies, treatment naive 
patients or treated patients after a washout period were in-
cluded. In other studies, however, a run-in design on timo-
lol was employed. In both situations, it is possible to draw 
conclusions on the total IOP lowering of the PTFC; however, 
several issues arise. One issue is how omitting the second 
timolol dose after a timolol twice daily run-in period and 
switching to a PTFC administered once daily is handled. The 
second issue is whether an IOP-related response criterion 
after a run-in period is included in case of a run-in design. 
This is of importance since one does not want to include 
timolol non-responders in these studies.
It is logical with fixed combinations that are administered 
morning or evening to document the time point of admin-
istration (am or pm). Certainly, if one is interested in the 
real efficacy of PTFCs it is essential to include as many 
time points as possible evenly distributed through the peak 
and trough periods when comparing these drugs. A few 
of the individual studies of this meta-analysis employed a 
more rigorous IOP evaluation protocol (i.e., when a com-
plete 24-hour IOP curve was performed). Consequently, by 
including only 3 measurements (9 am, 11 am, and 4 pm time 
points), one misses important data that better delineate the 
extent of IOP lowering throughout the peak and trough ef-
ficacy periods.
Meta-regression analysis could also be performed for po-
tential factors causing heterogeneity, such as run-in treat-
ment, timing of treatment, treatment duration, type of trial 
design parallel vs cross-over design, and number of IOP 
time points (22).
Extrapolating from their evidence the authors suggest 
greater efficacy for the bimatoprost-timolol fixed combina-
tion compared with the latanoprost-timolol and travoprost-
timolol fixed combinations.
therapy or intervention. The first meta-analysis has gener-
ally been credited to the statistician Karl Pearson in 1904 
(7) although Glass first defined the term meta-analysis in 
1976 in the social science literature (8). Since then the mer-
its and perils of meta-analysis continue to be debated in 
the medical literature (9-12). It is to be emphasized, how-
ever, that evidence is evolving; new studies are continually 
being published and their results may accord or be at vari-
ance with older studies. In some cases, this can result in 
revisions to the conclusions of previously published meta-
analyses (13-16). Moreover, the possibility exists that some 
meta-analyses that ignore the wider spectrum of clinical 
trials, such as unpublished studies, could lead to narrow, 
misleading interpretations (15).
The meta-analysis by Aptel et al, published in this issue, 
shows that all 3 PTFCs provide greater IOP reduction and 
a lower incidence of hyperemia than the 3 respective pros-
taglandin monotherapies. The direct comparisons reported 
herein suggest greater efficacy for the bimatoprost-timolol 
fixed combination compared with the latanoprost-timolol 
and the travoprost-timolol fixed combinations. This meta-
analysis confirmed that PTFCs can significantly enhance 
the efficacy of prostaglandin monotherapies and, at the 
same time, reduce one of their important side effects, 
conjunctival hyperemia. The present study confirms what 
we often see in clinical practice. As stated previously, the 
incremental efficacy of PTFCs, although statistically sig-
nificant and clinically meaningful, can be modest. This may 
reflect the robust efficacy and tolerability profile of pros-
taglandin monotherapies. It is now more difficult to reach 
further IOP reduction without compromising adherence. It 
remains to be seen what constitutes a meaningful incre-
mental IOP reduction. For at-risk and progressing patients 
even a 1 mmHg further IOP reduction is important. There-
fore, the findings of this meta-analysis are most welcome: 
adding timolol to a prostaglandin analogue in a fixed com-
bination provides measurable clinical value in terms of ef-
ficacy and tolerability.
It is difficult to compare the results of the present meta-
analysis to those of others. Three previously published 
meta-analyses (17-19) reported that, in agreement with 
this work, the efficacy of PTFCs is significantly greater than 
that of each of their separate components. This refers to 
the situation where the trial drug (timolol, prostaglandin, 
or PTFC) is initiated in treatment of naive patients, or in 
established patients after an appropriate washout period. 
However, it is to be emphasized that a conventional meta-
analysis is not the appropriate technique to apply a ranking 
of drugs, in this case IOP-lowering drugs, if appropriate 
head-to-head comparisons are not available. This meta-
analysis reports only the absolute IOP-lowering effects per 
study for 9 am, 11 am, 4 pm, and the mean daytime curve. 
The relative IOP decrease (related to the baseline IOP) 
would have been of clinical interest as well. Furthermore, 
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There may be a fundamental flaw in the selection process 
of the NICE meta-analysis. The basic assumption that since 
glaucoma is a lifelong disease only long-term clinical trials 
should be included largely depends on the question asked. 
If the clinical question in the meta-analysis was whether IOP 
lowering is effective in managing glaucoma and reducing 
progression then longer term studies are clearly needed. 
But if the question is whether PTFCs are safe and effec-
tive then all pertinent studies should have been included. 
The 2 studies that qualified for the NICE meta-analysis only 
really compare the efficacy of the latanoprost/timolol fixed 
combination versus latanoprost and timolol monotherapies 
(28, 29).
Further, it is important to emphasize that the design of 
these two studies tends to minimize the difference between 
the latanoprost/timolol fixed combination and latanoprost. 
For example, in the study by Higginbotham et al (29), a 
run-in period on timolol administered twice daily was fol-
lowed by 3 study arms: continuation of timolol, switch to 
latanoprost administered in the evening (20:00), or switch 
to the latanoprost/timolol fixed combination administered 
in the morning (08:00). The IOP measurements were taken 
at 08:00, 10:00, and 16:00. This design underestimated 
the efficacy of the PTFC given in the morning compared 
to latanoprost dosed in the evening. It was demonstrated 
by Alm and Stjernschantz (30) in a 3-month crossover trial 
that there is a statistically significant difference between 
latanoprost administered in the evening (–8.6 mmHg, 35%) 
and latanoprost administered in the morning (–7.8 mmHg, 
31%) (p<0.001). 
This meta-analysis clearly summarizes the evidence from 
available clinical trials and indirectly reflects what is pub-
lished in individual studies and also what every clinician 
experiences in real-life practice. Importantly, the results 
achieved to date employing a meta-analysis are highly de-
pendent on the range and quality of studies included. It is 
relevant here to emphasize that the chain of a meta-analy-
sis is as strong as the weakest individual randomized con-
trolled trial. Striving for both statistical and clinical homo-
geneity and correctly matching study designs is important. 
Future head-to-head studies that assess the true efficacy 
of PTFCs over a 24-hour period may eliminate inconsisten-
cies arising from key issues discussed before (selection of 
time points measuring the IOP, time of administration rela-
tive to the peak and trough efficacy of the fixed combina-
tion). There is much scope for further research into the as-
sessment of adherence and other advantages (tolerability) 
with PTFCs versus concomitant unfixed therapies. Finally, 
there is a major need to study the optimum treatment strat-
egies with fixed combinations in children.
Fixed combination drugs like the PTFCs can provide ef-
fective IOP control, enhance adherence and convenience, 
eliminate the washout effect, and significantly reduce ex-
posure to preservatives. In real-life practice PTFCs can of-
This conclusion should be interpreted with some caution 
since the direct comparisons between these fixed combi-
nations showed considerable heterogeneity (I2=97.6% at 9 
am, 97.8% at 11 am and at 4 am, and 96.8% for the mean 
diurnal curve). Further, the direct comparison between 
bimatoprost-timolol and travoprost-timolol fixed combina-
tions is based on a single study (23) in which patients who 
responded inadequately to the latanoprost-timolol fixed 
combination were switched to either bimatoprost-timolol 
or travoprost-timolol fixed combination therapy. This study 
introduces significant clinical heterogeneity. Study patients 
are, to a certain extent, suboptimal responders to timolol, 
latanoprost, or the latanoprost-timolol fixed combination.
The current meta-analysis by Aptel et al demonstrates that 
the 3 available PTFCs provide greater IOP reduction at all 
time points and a lower prevalence of conjunctival hyper-
emia than the 3 individual prostaglandin monotherapies. 
The impact of this conclusion in real-life clinical practice is 
important. It suggests that PTFCs are more effective and 
better tolerated, so they should be preferable to individ-
ual prostaglandin constituents when further IOP lowering 
is needed. It is likely that in real life the impact of these 
fixed combinations may be greater: better IOP control, 
less adverse events, and better adherence. Although these 
suggestions are reasonable, direct evidence has not been 
provided for these as yet. The current meta-analysis con-
tradicts the conclusions of the NICE meta-analysis, which 
reported only a small (0.3 mmHg) difference between PT-
FCs and prostaglandin analogues (24; Fig. 27, Appendix 
E). It should be noted that the results of this meta-analysis 
were made available on the Web, but were never published 
in a peer-reviewed journal. Importantly, the NICE meta-
analysis needs updating since several trials on PTFCs 
have been conducted and published since 2008 and even 
combined through meta-analysis (25-27). With regard to 
information sources used, it did not report the use of sup-
plementary approaches to identify studies, such as hand 
searching of journals, checking reference lists, searching 
trials registries or regulatory agency Web sites, contacting 
manufacturers, or contacting authors. Furthermore, in the 
databases searched there were no dates of coverage, or 
the dates last searched.
In order to make appropriate decisions about new agents, 
evaluation of the wider perspective, including unpublished 
studies, is required (16). Only 3 studies were eligible ac-
cording to the strict inclusion criteria of 6 months follow-
up employed by the NICE meta-analysis (24) and of those 
only 2 compare a single PTFC to monotherapies (28, 29). 
Instead of limiting the meta-analysis to studies with longer 
follow-up, it would have been more clinically relevant to 
include studies with shorter follow-up to see whether the 
results of studies with shorter follow-up were different from 
the few studies with longer follow-up through subgroup 
analysis or meta-regression analysis.
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ten be superior to unfixed concomitant therapy. There is 
still, however, limited verification for the benefits accrued 
and little is known concerning the comparative efficacy 
between them. As yet, there is no information on whether 
all fixed combinations improve long-term clinical outcome 
and this will be a promising line of future research. The 
possibility exists that PTFCs may prove instrumental in im-
proving management and prognosis in glaucoma.  
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